Cytochroma

About Cytochroma

Cytochroma, a life sciences company established in 2017 by Dr. Kate Cameron, operates from Roslin, near Edinburgh, Scotland, providing advanced alternatives to animal testing for drug discovery. Dr. Cameron's background includes a PhD in stem cell research from the University of Edinburgh, followed by six years of postdoctoral work focused on creating liver cells for regenerative medicine, which laid the groundwork for the company's core technology.

The company develops and manufactures human tissue models for research and drug development, specializing in creating functional in vitro models from induced pluripotent stem cells (iPSCs). Cytochroma serves pharmaceutical and biotech companies by providing tools for more accurate and ethical drug discovery. Its business model involves generating revenue through the sale of its cell model products and screening services, with future plans to engage in drug discovery directly and through partnerships.

Cytochroma's core offering consists of optimized iPSC-derived cell models, primarily focusing on liver (hepatocytes) and heart (cardiac fibroblasts) cells to create models for conditions like metabolic-associated fatty liver disease (MAFLD) and hypertrophic cardiomyopathy (HCM). A key differentiator is the company's ethically sourced and genetically diverse iPSC library, which includes donors from various ethnic backgrounds such as Native American, Asian, African, and European. This diversity addresses a significant gap in preclinical research and aligns with regulatory calls for more inclusive drug development, allowing clients to assess drug responses across different populations early in the process. The company employs a proprietary, scalable process using robotics and machine learning, making its screening platform significantly faster and more cost-effective than standard methods.